Mar 25, 2022 – ClinicalOTR3 announces first patient enrolled in a Phase I study of OTR4132-MD in Acute Ischemic Stroke (AIS).
Feb 10, 2022 – ClinicalOTR3 announces first patient enrolled in a post market clinical follow up on Cacipliq 20®..
Oct 8, 2021 – ClinicalOTR3 receives approval from ANSM to start new clinical trial with the application of a RGTA® product in ischemic stroke.
Jun 29, 2021 – CorporateOTR3 appoints new management teams as the company planned to launch a second generation of RGTA® products.
